Se crea la Lung Ambition Alliance con el objetivo de duplicar el índice de supervivencia de cinco años en pacientes con cáncer de pulmón para el 2025 LONDRES, July 08, 2019 (GLOBE NEWSWIRE) -- En el día de hoy, la Asociación Internacional para el Estudio del Cáncer de Pulmón (IASLC), Guardant Health, la Coalición Mundial del Cáncer de Pulmón...

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025 LONDON, July 08, 2019 (GLOBE NEWSWIRE) -- Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca...

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 ≥25% and <25% groups in 2nd-line non-small cell lung cancer Phase I Study 10 data shows clinical activity with combination...

AstraZeneca Does Not Recommend or Endorse Unsolicited 'Mini-Tender' Offer London, UK, March 22, 2004 (PRIMEZONE) -- AstraZeneca Does Not Recommend or Endorse Unsolicited "Mini-Tender" Offer AstraZeneca PLC announced today that it has...